The company began publicly trading on the Nasdaq on Oct. 20 under the ticker “PRIME.”
Prime Medicine’s flagship gene-editing product has the potential to repair 90 percent of disease-causing genetic mutations, according to an Oct. 24 Prime news release provided to Becker’s.
J.P. Morgan, Goldman Sachs, Morgan Stanley and Jefferies serve as book-running managers for the offering.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
